MedPath Search

Clinical Trials

Find the latest clinical trials by condition, location & phase

Browse and search for drug monographs and related information

Approved pharmaceutical products by global regulatory authorities

Explore a comprehensive list of organizations, including their profiles and details

Latest updates on clinical trials, pharmaceuticals, and healthcare companies

|

Filters

Study Phase

Early Phase 1

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

Phase 4

Not Applicable

Recruitment Status

Recruiting

Not yet recruiting

Active, not recruiting

Completed

Suspended

Terminated

Withdrawn

Study Type

Interventional

Observational

Expanded Access

Others

Eligibility Sex

All

Female

Male

Healthy Volunteers

All

Include

Exclude

Found 540544 clinical trials

Sort by:

Validation of Artificial Intelligence-based Digital Anthropometry Applications for Estimating Body Composition.

Recruiting

Conditions: Body Composition

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Dynamical Business and Science Society - DBSS International SAS

Target Recruit Count: 130

Registration Number: NCT07003516

Locations: 🇨🇴
Universidad CES, Medellin, Antioquia, Colombia
🇨🇴
Fundación Universitaria del Área Andina, Bogota, Colombia

DOAC - Dosing Options in AntiCoagulation Prophylaxis

Phase 3

Not yet recruiting

Conditions: Cancer
VTE (Venous Thromboembolism)

Interventions: Drug: Apixaban 2.5 mg twice daily
Drug: Apixaban 5 mg once daily
Drug: No anticoagulation

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: University of Vermont

Target Recruit Count: 996

Registration Number: NCT07005024

Locations: 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Phase 1

Not yet recruiting

Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)

Interventions: Drug: Dual-targeting BCMA-CD19 CAR-T cell infusion

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Beijing GoBroad Hospital

Target Recruit Count: 18

Registration Number: NCT07003555

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

Phase 2

Recruiting

Conditions: Colo-rectal Cancer
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

Interventions: Drug: cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT07003022

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT

Conditions: Thalassemia in Children

Interventions: Drug: Hetrombopag

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine

Target Recruit Count: 30

Registration Number: NCT07003269

Locations: 🇨🇳
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, Hainan, China

Diagnostic Value of Confocal Laser Endomicroscopy (CelTouch) for Peripheral Lung Lesions

Recruiting

Conditions: Peripheral Pulmonary Lesion

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Guangzhou Medical University

Target Recruit Count: 286

Registration Number: NCT07004946

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510163, Guangzhou, Guangdong, China

Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency

Not Applicable

Recruiting

Conditions: Primary Immunodeficiency Diseases (PID)

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Dr. Hatice Dönmez

Target Recruit Count: 32

Registration Number: NCT07004803

Locations: 🇹🇷
Karamanoglu Mehmetbey University, Karaman, Turkey

Cardiometabolic Risk Factors Associated With Multidrug-Resistant Tuberculosis

Completed

Conditions: Tuberculosis (TB)

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: B.P. Koirala Institute of Health Sciences

Target Recruit Count: 183

Registration Number: NCT07003581

Locations: 🇳🇵
Mustang Hospital, Jomsom, Nepal

COMPARISON BETWEEN THE EFFECTS OF MULLIGAN AND MAITLAND MOBILIZATION ON PATELLOFEMORAL PAIN SYNDROME

Not Applicable

Recruiting

Conditions: Patellofemoral Pain Syndrome

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Foundation University Islamabad

Target Recruit Count: 40

Registration Number: NCT07004881

Locations: 🇵🇰
Foundation University College of Physical Therapy, Islamabad, Pakistan

Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Small Cell Lung Cancer
Immnunotherapy
Second-line

Interventions: Drug: Adebelizumab combined with irinotecan liposome as second-line therapy

First Posted Date: 2025-06-04

Last Posted Date: 2025-06-04

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 46

Registration Number: NCT07004712

Locations: 🇨🇳
Peking university cancer hospital, Beijing, Haidian, China

Prev
1
42
43
44
45
46
100
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy